



Atrial Fibrillation Overview and Updates

Salvatore Savona, MD, FACC, FHRS

Associate Professor - Clinical
Department of Internal Medicine
Division of Cardiovascular Medicine

The Ohio State University Wexner Medical Center

MedNet21
Center for Continuing Medical Education

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

1

Disclosures

- Consultant
 - Biosense Webster
 - Medtronic

2

Objectives

1. Review Atrial Fibrillation (AF) evaluation
2. Highlight Recent Guideline Updates
3. Recognize importance of lifestyle and risk factor modification
4. Discuss stroke prevention
5. Understand differences in rate and rhythm management
6. Review commonly used antiarrhythmic medications
7. Discuss the role of catheter ablation
8. Discuss the role of left atrial appendage occlusion


3

Why is AF important?

- 3-6 million people estimated to have AF in the US
- Projected to increase to 6-16 million by 2050
- Lifetime risk of developing AF from age 40-95:
 - 26% for men
 - 23% for women



Courtesy of Dr. Liu



4

Why is AF important?



- >467,000 annual hospitalizations
- 2x as likely to be hospitalized
- >99,000 deaths per year




- Adds \$8,700 per year per patient
- Adds \$26 billion to US healthcare annually

Courtesy of Dr. Liu

5

Pathophysiology



6


What is AF?



7


What is AF?

Video



8

What is not Afib?



The figure displays four ECG strips illustrating conditions that are not atrial fibrillation:

- Artifact:** Shows irregular baseline and QRS complexes due to external noise or movement.
- Sinus with premature atrial contractions:** Shows a regular sinus rhythm with occasional premature, wide, and bizarre QRS complexes.
- Atrial flutter:** Shows a regular, rapid atrial rate with characteristic sawtooth flutter waves.
- Multifocal Atrial Tachycardia:** Shows an irregularly irregular rhythm with multiple different P wave morphologies.

9

Evaluation

EKG	• Markers of other heart disease (LVH, ischemia) • Pre-excitation • QT interval (important for certain anti-arrhythmics)
Echo	• Assess LV function, valvular disease • Left atrial size
Labs	• Chemistry, CBC • Thyroid function

10

Major Updates

2023 ACC/AHA/ACCP/HRS Guidelines

1. Stages of AF
2. AF Risk Factor Modification and Prevention
3. Flexibility of Stroke Prevention Risk Scores
4. Incorporation of Stroke Risk "Modifiers"
5. Early Rhythm Control
6. Class 1 Indication for AF Ablation in Select Populations
7. Class 1 Indication for AF Ablation in HFrEF
8. Device Detected AF Updates
9. Left Atrial Appendage Occlusion Recommendations (Increase to 2a for select populations)
10. Importance of AF Detected during an Acute Illness

Inglis, Joel A., et al. "2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." *Circulation* 148.1 (2023): e1-e56.

11

Stages of AF Disease Continuum

Prior	Current
• Paroxysmal • Persistent • Long-Standing Persistent • Permanent	• Stage 1: At Risk • Stage 2: Pre-AF • Stage 3: AF • 3A: Paroxysmal • 3B: Persistent • 3C: Long-standing Persistent • 3D: Successful Ablation • Stage 4 Permanent


Inglis, Joel A., et al. "2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." *Circulation* 148.1 (2023): e1-e56.

THE OHIO STATE UNIVERSITY
WEINER MEDICAL CENTER

12

Stage Based Management


- Common Thread: Treat Modifiable Risk Factors



Jaglar, José A., et al. "2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." *Circulation* 149.3 (2024): e1-e156.

13

Risk factors for developing AF



14

Risk Factor Modification and Prevention


Weight Management ≥10% Weight Loss Target meaningful and sustained weight reduction	Physical Activity ≥210 min/week Moderate-to-vigorous exercise
Smoking Cessation Eliminate Tobacco Use Offer guideline-directed cessation therapies	Alcohol Reduction ≤3 Drinks/Week Avoid binge drinking; abstinence preferred
Cardiometabolic Optimization Diabetes & Hypertension Evidence-based risk factor control	Sleep Health Screen for OSA Identify and treat sleep disorders

Jaglar, José A., et al. "2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." *Circulation* 149.3 (2024): e1-e156.

15

Obesity and AF

- Obesity is a strong risk factor for AF
- Target a weight loss of at least 10% to help reduce AF burden
- Bariatric surgery in obese patients has been associated with reduced risk of new AF and recurrence after ablation.
- For overweight and obese patients with AF, weight loss combined with risk factor modification is recommended.
- Role for GLP-1?



Courtesy of Dr. Liu with adaptation

Circulation 2020; 141:e750-e772. DOI: 10.1161/CIR.0000000000000714

16

Caffeine Intake



No Benefit to Recommend Caffeine Abstinence to Prevent Recurrence (Class III)

May reduce symptoms in patients who report Caffeine triggers

Juglar, José A., et al. "2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." *Circulation* 149.3 (2024): e1-e155.

17

Stroke in AF

800,000 Strokes/Year

87% Ischemic
13% Hemorrhagic (10% ICH, 3% SAH)

AF is the most frequent major complication linked to stroke

5x
Higher stroke risk in non-valvular AF

8-36%
1-year mortality varies by age & sex



↑ Recurrence
More disability and increased mortality

Juglar, José A., et al. "2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." *Circulation* 149.3 (2024): e1-e155.

18

Stroke Prevention

Video

Brain Medical Communications, Inc., CC BY 3.0 via Wikimedia Commons

19

Stroke Risk Assessment

STROKE ↑

CHA₂DS₂-VASc | HAS-BLED
ATRIA ↔ ATRIA
GARFIELD | HEMORR₂HAGES

BLEEDING ↓

Juglar, José A., et al. "2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." *Circulation* 149.3 (2024): e1-e155.

20


CHA₂DS₂VASc Score

Letter	Risk factor	Score
C	Congestive heart failure	1
H	Hypertension	1
A ₂	Age ≥ 75	2
D	Diabetes	1
S ₂	Stroke, TIA, thromboembolism	2
V	Vascular disease (myocardial infarction, peripheral arterial disease, aortic plaque)	1
A	Age 65-74	1
S	Sex category (female sex)	1


CHA ₂ DS ₂ VASc Score	Annual Stroke Rate
0	0.2%
1	0.6%
2	2.2%
3	3.2%
4	4.8%
5	7.2%
6	9.7%
7	11.1%
8	11%
9	12.2%

Juglar, José A., et al. "2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." "Circulation 148.1 (2024): e1-e156.


21



22



23



24

DOACs for Afib						
	Mechanism	Comparison to warfarin	Kinetics	Dosing	Dosing adjustments	Reversal agent
Dabigatran	Direct thrombin inhibitor	110mg: stroke rates similar to warfarin, lower major hemorrhage 150mg: stroke rate lower than warfarin, similar major hemorrhage	$T^{1/2} = 12-17$ hrs Peak effect 2hrs	150mg BID	75mg BID if CrCl 15-30 mL/min - Avoid use if CrCl <15 mL/min	- Idarucizumab - Prothrombin complex concentrate (PCC)
Rivaroxaban	Direct factor Xa inhibitor	Non-inferior to warfarin for stroke prevention, no difference in major bleeding, less frequent ICH and fatal bleeding	$T^{1/2} = 5-9$ hrs Peak effect 3hrs	20mg daily with largest meal of day (evening)	15mg daily with evening meal if CrCl 15-50 mL/min - Avoid use if CrCl ≤15 mL/min	- Andexanet alfa - PCC
Apixaban	Direct factor Xa inhibitor	Superior to warfarin for stroke prevention, less bleeding and lower mortality	$T^{1/2} = 12$ hrs Peak effect 3hrs	5mg BID	2.5mg BID if 2 of the following: age ≥80 yrs, body weight ≤60 kg, or serum Cr ≥1.5 mg/dL - No other adjustment for ESRD	- Andexanet alfa - PCC
Edoxaban	Direct factor Xa inhibitor	Non-inferior to warfarin for stroke prevention, lower rates of bleeding	$T^{1/2} = 10-14$ hrs Peak effect 2hrs	60mg daily	- Avoid use if CrCl >95 mL/min 30mg daily if CrCl 15-50 mL/min - Avoid use if CrCl <15 mL/min	PCC

Courtesy of Dr. Liu

25

Monitoring devices



Holter monitor



Event monitor/mobile cardiac telemetry



Implantable loop recorder



Pacemaker/defibrillator



Personal devices

BruceBlais, CC BY-SA 4.0, via Wikimedia Commons
Hellerhoff, CC BY-SA 4.0, via Wikimedia Commons
Kamenis, CC BY-SA 4.0, via Wikimedia Commons
Brian Adduci, CC BY-SA 4.0, via Wikimedia Commons
Alamy, CC BY-SA 4.0, via Wikimedia Commons
Courtesy of Dr. Liu

26

Device Detected Atrial Fibrillation



Initial Diagnosis

Electrocardiogram
Intracardiac Tracing (ie atrial pacemaker lead)



Wearable monitors are reasonable to detect duration and burden of AF with automated algorithms



Consumer based ECG data can be used for monitoring

27 |


27

Device Detected Atrial High Rate Episode (AHRE)


AHRE ≥24 hrs + CHADSVASC ≥2	Anticoagulation Reasonable
5min < AHRE < 24hrs + CHADSVASC ≥3	Anticoagulation Reasonable
AHRE <5min	No anticoagulation

Jonglar, José A., et al. "2023 ACC/AHA/ACCPHRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." *Circulation* 148.1 (2024): e1-e106.
Trade Secret, Confidential, Proprietary, Do Not Copy | OSU Wexner Medical Center © 2018

28



29



30

Rate Control


- **Patient Population**
 - Permanent atrial fibrillation
 - Asymptomatic
 - Preserved LV function
- **Acute Management**
 - IV beta blocker or nondihydropyridine calcium channel blocker
 - Avoid nondihydropyridine calcium channel blocker in decompensated heart failure
- **Chronic HR Goal**
 - Resting heart rate < 80bpm
 - If asymptomatic and normal LV function, can consider a more lenient goal (<110bpm)

January, Craig T., et al. "2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society." *Journal of the American College of Cardiology* 64.21 (2014): e1-e76.

31

Class	Example	Mechanism	Side Effects
Beta Blocker	• Metoprolol • Carvedilol • Atenolol • Propranolol	Rate control achieved by inhibiting beta-1 receptors	• Depression • Erectile Dysfunction • Bradycardia • Fatigue
Nondihydropyridine Calcium Channel Blocker	• Diltiazem • Verapamil	Inhibits calcium ion entry during depolarization	• Constipation • Lower Extremity Edema
Cardiac Glycoside	Digoxin	Suppression of AV node conduction via inhibition of Na/K ATPase -> increased intracellular Ca	• Too many to list • Requires drug level monitoring • Toxicity may require Digi-Fab

32




33

Rhythm Control

- Patient Population**
 - Symptomatic
 - LV dysfunction and heart failure
 - Non permanent atrial fibrillation
- Acute Management**
 - Electrical or chemical cardioversion
 - Prior to cardioversion
 - 3-4 weeks of uninterrupted anticoagulation regardless of CHADSVASC score or onset within 48 hours of cardioversion
 - Transesophageal echo or CT pulmonary vein showing no left atrial or left atrial appendage thrombus
 - Following Cardioversion
 - 4 weeks of uninterrupted anticoagulation, regardless of CHADSVASC score

January, Craig T., et al. "2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society." *Journal of the American College of Cardiology* 64.21 (2014): e1-e76.
<https://commons.wikimedia.org/wiki/File:Cardioversion.png> - National Heart Lung and Blood Institute (NIH) - Author - [jmarcho](#)

34



35

Antiarrhythmic Maintenance of Sinus Rhythm					
Class	Mechanism	Drug	Monitoring	Contraindications	Notes
Ic	Na Channel Blockade	- Flecainide - Propafenone	- Baseline ECG - Stress Test - Renal and Liver	- Structural heart disease - Conduction disease	Must be taking with an AV nodal blocking agent
III	K Channel Blockade	- Sotalol - Dofetilide - Dronedronone	- QT/QTc - Renal Function	- ESRD - Prolonged QT - Bradyarrhythmia	Do not use dronedronone in symptomatic heart failure, NYHA IV or permanent AF
Many	Na, K, CCB, and BB	Amiodarone	- Thyroid - Liver - Pulmonary (CXR and DLCO)	- Pulmonary and liver disease - Hyperthyroid - Heart block - Iodine hypersensitivity	- Photosensitivity - Ocular and neurologic involvement

36

Pill in the Pocket

Class 1C AAD

Give AV nodal blocking agent (diltiazem, verapamil, metoprolol, etc) and DOAC

30 minutes later given Class 1c agent

- Propafenone 600mg (>70kg) or 450mg (≤70kg)
- Flecainide 300mg (>70kg) or 200mg (≤70kg)

Monitor for 6 hours on telemetry post first dose

BP every 30 min

ECG every 2 hours

If QRS increases >50%, stop therapy

Severe toxicity treated with hypertonic sodium bicarb

37 | Trade Secret, Confidential, Proprietary, Do Not Copy | ©2018 Warner Medical Center ©2018

37

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Trial

- 2002 in New England Journal of Medicine
- Compared mortality in rate vs rhythm control strategy in ~4000 patients
- Majority of rate control- beta blocker and digoxin
- Majority of rhythm control- amiodarone and sotalol
- Higher incidence in rhythm control:
 - pulmonary event (7.3 vs 1.3)
 - gastrointestinal event (8.0 vs 2.1)
 - bradycardia (6.0 vs. 4.2)
 - prolonged QTc (1.9 vs 0.3)
- Conclusion- "Management of atrial fibrillation with the rhythm-control strategy offers no survival advantage over the rate-control strategy, and there are potential advantages, such as a lower risk of adverse drug effects, with the rate-control strategy"

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. "A comparison of rate control and rhythm control in patients with atrial fibrillation." *New England Journal of Medicine* 347:23 (2002): 1825-1833.

38

Why Choose Rhythm Control?

- Much has changed since 2002
- Only 14 patients received an AF ablation
- Therapeutic INR in only 62.3%
- Sotalol downgraded to a 2b recommendation
- **Follow-up Analysis**
 - 5 year follow-up showed a greater risk of heart failure in rate control strategy (21.4% vs 16.4%)
 - Increase in total mortality (HR 2.83), cardiac mortality (4.27) and hospitalization (HR 3.04)
 - Risk factors for heart failure
 - Rate >80 bpm
 - AF burden, especially >75%





• See A. Sakuma S. Impact of initial heart failure emergence on clinical outcomes of atrial fibrillation patients in the AFFIRM trial. *Am Heart J*. 2020 Feb;230:1-11. doi: 10.1016/j.ahj.2019.10.005. Epub 2019 Oct 28. PMID: 31756395.

• Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. "A comparison of rate control and rhythm control in patients with atrial fibrillation." *New England Journal of Medicine* 347:23 (2002): 1825-1833.

• https://commons.wikimedia.org/wiki/File:2016_Soft_Journal_A1_Memo_West_Midlands_Ambulance_Service_3.0.jpg : Author – Makizox CC BY-SA 4.0

39

Atrial Fibrillation Ablation



https://commons.wikimedia.org/wiki/File:Herz_Lungenvenenablation.png


Modified by [21000000](#) from the modified version by [Duke](#) of the [original](#) heart diagram by [Wikipedia](#).

File is licensed under the [Creative Commons Attribution-Share Alike 2.0 license](#), [2.0 license](#), and [2.0 license](#) terms.

40

Pulsed Field Ablation (PFA)

NONTHERMAL • TISSUE SELECTIVE
Electroporation causes cell death while minimizing collateral injury



Mechanism	Advantages	Risks
Electrical field applied to cells → membrane permeability Cell death	Similar efficacy Increased procedural efficiency Lower phrenic nerve & esophageal injury	Coronary vein stenosis Hemolysis Stroke

Key Message: Pulsed field ablation offers tissue-selective lesion creation with improved efficiency and a favorable safety profile compared with thermal ablation technologies.

Hartl, Stefan, et al. "Benefits and pitfalls of pulsed field ablation." *Korean circulation journal* 33.5 (2023): 273-293.

41

Early AF Ablation

↓33% Stroke Reduction	↓16% Mortality Reduction	54% vs 29% Symptom improvement	42.9% vs 67.8% AF Recurrence
--------------------------	-----------------------------	-----------------------------------	---------------------------------

Timing
EAST-AFNET 4: Early rhythm control reduced stroke by one-third and lowered all-cause mortality by 16%.

Symptoms & Burden
STOP AF: 54% symptom improvement vs 29% with AAD.
EARLY AF: 1-year recurrence 42.9% with ablation vs 67.8% with AAD.

Key Message: Earlier AF ablation is associated with improved clinical outcomes, symptom relief, and lower recurrence compared with antiarrhythmic drug therapy.

• Kirchhof, Paulus, et al. "Early rhythm-control therapy in patients with atrial fibrillation." *New England Journal of Medicine* 383.14 (2020): 1305-1316.
• Wazni, Oussama M., et al. "Cryablation ablation as initial therapy for atrial fibrillation." *New England Journal of Medicine* 384.4 (2021): 316-324.
• Andrade, Jason G., et al. "Cryablation or drug therapy for initial treatment of atrial fibrillation." *New England Journal of Medicine* 384.4 (2021): 305-315.

42

AF Ablation and Mortality

CABANA: No difference in all cause mortality
Improvement in hospitalization and AF recurrence



CASTLE-AF: Significant improvement in mortality in systolic heart failure (HR 0.56)



Author: Paradise.Biz - CC BY-SA 4.0 - No changes

• Packer DL, Mark DB, Roth RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardio Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. *JAMA*. 2019;321(13):1261-1274. doi:10.1001/jama.2019.0693
• https://commons.wikimedia.org/wiki/File:Castle_Cabana_af_Paradise_biz_MelH27541_1_Mel.jpg
• Marrouche, Nassir F., et al. "Catheter ablation for atrial fibrillation with heart failure." *New England Journal of Medicine* 378.5 (2018): 417-427.
• https://commons.wikimedia.org/wiki/File:Neurochirurgien_Castle_2024.jpg

43

Left Atrial Appendage Closure




Candidates
Non-compliant or labile INR
High risk lifestyle
Severe Bleeding due to Non-reversible cause
Spontaneous intracranial or intraspinal bleeding
Serious bleeding due to recurrent falls



Evaluation
CHADSVASC ≥ 2
Suitable for anticoagulation
Appropriate candidate
No other need for anticoagulation (mechanical valve, left ventricular thrombus, etc.)

44 |



44

CT Preplanning


45

**Transseptal with ICE Guidance
Video**

46

Videos**Deployment****Tug Test**


47

Contrast Injection**Video**

48

Deployment


Video



48 | Trade Secret, Confidential, Proprietary, Do Not Copy | OSU Wexner Medical Center © 2018

49

Post LAAO Management



50

AF in Acute Illness



Significant risk of recurrent AF when diagnosed during an acute illness

- Recurrence rates range from 39% - 68 %

Outpatient follow-up specifically focused on AF risk recommended

- Higher rates of HF, stroke, death

Anticoagulation benefit is uncertain in acute illness due to sepsis during critical illness

- No significant association with stroke or bleeding at 3 year

https://commons.wikimedia.org/wiki/File:Dr_Moosa_Kurhi_OA.jpg

51

Conclusions

- Atrial fibrillation remains a significant burden for patients and the medical system
- Appropriate prevention of stroke based on risk factors is of utmost importance
- Risk factor modification can have a significant improvement in atrial fibrillation burden
- Rhythm control options, especially early in the course of disease can reduce the burden of disease and improve outcomes
- Ablation therapy is safe and efficacious, with a larger role in the management of atrial fibrillation
- Left Atrial Appendage Occlusion is an option for high risk patients

52